Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 9/20 | 0.65 |
| ▸ | ACHE | P22303 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.59 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.58 |
| ▸ | HRH2 | P25021 | 1/20 | 0.58 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL627575 | 0.81 | BCHE (0.65) | BCHEACHEALDH1A1MAPK1USP2 | |
| SCHEMBL4759685 | 0.81 | BCHE (0.65) | BCHEACHEALDH1A1MAPK1USP2 | |
| SCHEMBL2681239 | 0.81 | BCHE (0.70) | BCHEACHEALDH1A1MAPK1USP2 | |
| SCHEMBL7966578 | 0.79 | BCHE (1.00) | BCHEACHEALDH1A1MAPK1ADRB3 | |
| SCHEMBL11618894 | 0.79 | BCHE (0.67) | BCHEACHEALDH1A1MAPK1USP2 | |
| SCHEMBL20272375 | 0.79 | BCHE (0.71) | BCHEACHEALDH1A1MAPK1USP2 | |
| SCHEMBL7982855 | 0.79 | BCHE (0.67) | BCHEACHEMAPK1NOX1ADRB3 | |
| SCHEMBL7350072 | 0.78 | BCHE (0.63) | BCHEACHEALDH1A1NOX1HRH2 | |
| SCHEMBL8739172 | 0.78 | BCHE (0.76) | BCHEACHENOX1MEN1KMT2A | |
| SCHEMBL24864781 | 0.77 | BCHE (0.59) | BCHEACHEALDH1A1MAPK1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200306258-A1 | TARGETING THE TLK1/NEK1 AXIS IN PROSTATE CANCER | UNITED STATES GOVERNMENT | 2020-10-01 | — | — | US | disclosed |
| EP-1765797-A4 | PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE | UNIV KANSAS CT FOR RES INC (US) | 2008-02-06 | — | — | EP | disclosed |
| EP-1765797-A1 | PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE | University of Kansas Center for Research, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006002441-A1 | PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE | UNIVERSITY OF KANSAS (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050288279-A1 | Phenothiazine derivatives and their method of use | KANSAS MEDICAL CENTER, UNIVERSITY OF | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288279-A1 | Phenothiazine derivatives and their method of use | SHBG, GPR119, BRDT | BCHE 3057/4885ACHE 2804/4885ALDH1A1 2344/4885 |
| US-20200306258-A1 | TARGETING THE TLK1/NEK1 AXIS IN PROSTATE CANCER | NEK11, NEK1, NEK10 | BCHE 4051/4885ACHE 4296/4885ALDH1A1 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.